SEARCH

SEARCH BY CITATION

Disclaimer: Supplementary materials have been peer-reviewed but not copyedited.

FilenameFormatSizeDescription
pmic7204-sup-0001-TableS1.doc28KSupplementary Table 1. Clinical characteristics of the primary Sjögren's syndrome (pSS) and healthy control (HC) subjects.
pmic7204-sup-0002-TableS2.xls195KSupplementary Table 2. Identification of proteins in parotid saliva with a minimum of two unique peptides by MudPIT.
pmic7204-sup-0003-TableS3.xls34KSupplementary Table 3. Identification of proteins in parotid saliva with a minimum of two unique peptides by RP.
pmic7204-sup-0004-TableS4.xls28KSupplementary Table 4. Details of the protein name, peptide sequence and precursor mass of five proteins used for targeted label-free quantification.
pmic7204-sup-0005-FigureS1.tif1376KFigure 1A. Canonical pathways identified by ingenuity pathway analyses (IPA). (A) Significant pathways (n = 32) mapped to up-regulated proteins.
pmic7204-sup-0006-FigureS2.tif2388KFigure 1B. (B) Significant pathways (n = 68) mapped to proteins identified only in pSS patients. Values on each histogram correspond to the number of proteins involved in each pathway.
pmic7204-sup-0007-FigureS3.tif293KFigure 2. Label-free quantification of selected differentially expressed proteins between pSS and HC. (A) Modest change in abundance of cystatin C, (B) Up-regulation of lysozyme C. Primary Sjögren's syndrome = pSS and Healthy control = HC subjects.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.